Current and emerging therapies for Alzheimer's disease - PubMed (original) (raw)
Review
Current and emerging therapies for Alzheimer's disease
Haakon B Nygaard. Clin Ther. 2013 Oct.
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative disorder, with a rapidly increasing worldwide prevalence. Although no cure for AD has yet been found, substantial progress has been made in our understanding of AD pathogenesis. This progress has led to the development of numerous promising compounds in various stages of clinical testing. In this review, the current pharmacologic treatments for AD are discussed in detail, followed by an overview of the main experimental strategies that will shape AD therapeutics over the next decade.
© 2013 Elsevier HS Journals, Inc. All rights reserved.
Similar articles
- New and emerging treatments for Alzheimer's disease.
Corbett A, Smith J, Ballard C. Corbett A, et al. Expert Rev Neurother. 2012 May;12(5):535-43. doi: 10.1586/ern.12.43. Expert Rev Neurother. 2012. PMID: 22550982 Review. - Immunotherapy against amyloid pathology in Alzheimer's disease.
Galimberti D, Ghezzi L, Scarpini E. Galimberti D, et al. J Neurol Sci. 2013 Oct 15;333(1-2):50-4. doi: 10.1016/j.jns.2012.12.013. Epub 2013 Jan 5. J Neurol Sci. 2013. PMID: 23299047 Review. - A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
Schenk DB, Seubert P, Grundman M, Black R. Schenk DB, et al. Neurodegener Dis. 2005;2(5):255-60. doi: 10.1159/000090365. Neurodegener Dis. 2005. PMID: 16909006 Review. - Therapeutic options in Alzheimer's disease.
Moreira PI, Zhu X, Nunomura A, Smith MA, Perry G. Moreira PI, et al. Expert Rev Neurother. 2006 Jun;6(6):897-910. doi: 10.1586/14737175.6.6.897. Expert Rev Neurother. 2006. PMID: 16784412 Review. - Beyond amyloid: the future of therapeutics for Alzheimer's disease.
Lane RF, Shineman DW, Steele JW, Lee LB, Fillit HM. Lane RF, et al. Adv Pharmacol. 2012;64:213-71. doi: 10.1016/B978-0-12-394816-8.00007-6. Adv Pharmacol. 2012. PMID: 22840749 Review.
Cited by
- Focused Ultrasound-Induced Blood-Brain Barrier Opening Enhances GSK-3 Inhibitor Delivery for Amyloid-Beta Plaque Reduction.
Hsu PH, Lin YT, Chung YH, Lin KJ, Yang LY, Yen TC, Liu HL. Hsu PH, et al. Sci Rep. 2018 Aug 27;8(1):12882. doi: 10.1038/s41598-018-31071-8. Sci Rep. 2018. PMID: 30150769 Free PMC article. - Targeting Fyn Kinase in Alzheimer's Disease.
Nygaard HB. Nygaard HB. Biol Psychiatry. 2018 Feb 15;83(4):369-376. doi: 10.1016/j.biopsych.2017.06.004. Epub 2017 Jun 13. Biol Psychiatry. 2018. PMID: 28709498 Free PMC article. Review. - Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis.
Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Santos CY, et al. Alzheimers Dement (Amst). 2017 Feb 9;7:69-87. doi: 10.1016/j.dadm.2017.01.005. eCollection 2017. Alzheimers Dement (Amst). 2017. PMID: 28275702 Free PMC article. Review. - The Roles of Exercise and Yoga in Ameliorating Depression as a Risk Factor for Cognitive Decline.
Mathersul DC, Rosenbaum S. Mathersul DC, et al. Evid Based Complement Alternat Med. 2016;2016:4612953. doi: 10.1155/2016/4612953. Epub 2016 Dec 1. Evid Based Complement Alternat Med. 2016. PMID: 28044084 Free PMC article. Review. - The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease.
Gadhave K, Bolshette N, Ahire A, Pardeshi R, Thakur K, Trandafir C, Istrate A, Ahmed S, Lahkar M, Muresanu DF, Balea M. Gadhave K, et al. J Cell Mol Med. 2016 Jul;20(7):1392-407. doi: 10.1111/jcmm.12817. Epub 2016 Mar 29. J Cell Mol Med. 2016. PMID: 27028664 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical